Literature DB >> 28374816

Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C.

Kohtaro Ooka1, James J Connolly1, Joseph K Lim2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28374816     DOI： 10.1038/ajg.2017.87

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  18 in total

1.  Early Patterns of Sofosbuvir Utilization by State Medicaid Programs.

Authors:  Joshua M Liao; Michael A Fischer
Journal:  N Engl J Med       Date:  2015-09-24       Impact factor: 91.245

2.  A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service.

Authors:  Kirsten Westerhout; Maarten Treur; Angelika Mehnert; Katie Pascoe; Imran Ladha; Jonathan Belsey
Journal:  J Med Econ       Date:  2015-07-06       Impact factor: 2.448

3.  Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs.

Authors:  Lauren A Canary; R Monina Klevens; Scott D Holmberg
Journal:  Ann Intern Med       Date:  2015-08-04       Impact factor: 25.391

4.  Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.

Authors:  Vincent Lo Re; Charitha Gowda; Paul N Urick; Joshua T Halladay; Amanda Binkley; Dena M Carbonari; Kathryn Battista; Cassandra Peleckis; Jody Gilmore; Jason A Roy; Jalpa A Doshi; Peter P Reese; K Rajender Reddy; Jay R Kostman
Journal:  Clin Gastroenterol Hepatol       Date:  2016-04-05       Impact factor: 11.382

Review 5.  Access to treatment for hepatitis C virus infection: time to put patients first.

Authors:  Brian R Edlin
Journal:  Lancet Infect Dis       Date:  2016-07-13       Impact factor: 25.071

6.  Trends in compulsory licensing of pharmaceuticals since the Doha Declaration: a database analysis.

Authors:  Reed Beall; Randall Kuhn
Journal:  PLoS Med       Date:  2012-01-10       Impact factor: 11.069

7.  Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.

Authors:  Sai Zhang; Nathaniel D Bastian; Paul M Griffin
Journal:  BMC Gastroenterol       Date:  2015-08-05       Impact factor: 3.067

Review 8.  Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States.

Authors:  Elana S Rosenthal; Camilla S Graham
Journal:  Infect Agent Cancer       Date:  2016-05-16       Impact factor: 2.965

9.  A Revolution in Treatment for Hepatitis C Infection: Mitigating the Budgetary Impact.

Authors:  Elliot Marseille; James G Kahn
Journal:  PLoS Med       Date:  2016-05-31       Impact factor: 11.613

10.  Liver Stiffness Decreases Rapidly in Response to Successful Hepatitis C Treatment and Then Plateaus.

Authors:  Sweta Chekuri; Jillian Nickerson; Kian Bichoupan; Roberta Sefcik; Kamini Doobay; Sanders Chang; David DelBello; Alyson Harty; Douglas T Dieterich; Ponni V Perumalswami; Andrea D Branch
Journal:  PLoS One       Date:  2016-07-21       Impact factor: 3.240
View more
  16 in total

1.  Response to Liu et al.

Authors:  Kohtaro Ooka; James J Connolly; Joseph K Lim
Journal:  Am J Gastroenterol       Date:  2017-11       Impact factor: 10.864

2.  Cost-Effective but Unaffordable and Unequal Hepatitis C Treatment in the US.

Authors:  Xibei Liu; Jay J Shen; Jeong Lim Lee; Ji Won Yoo
Journal:  Am J Gastroenterol       Date:  2017-11       Impact factor: 10.864

3.  HCV treatment barriers among HIV/HCV co-infected patients in the US: a qualitative study to understand low uptake among marginalized populations in the DAA era.

Authors:  Tessa M Nápoles; Abigail W Batchelder; Ada Lin; Lissa Moran; Mallory O Johnson; Martha Shumway; Anne F Luetkemeyer; Marion G Peters; Kellene V Eagen; Elise D Riley
Journal:  J Public Health (Oxf)       Date:  2019-12-20       Impact factor: 2.341

4.  Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting.

Authors:  M Eugenia Socías; Lianping Ti; Evan Wood; Ekaterina Nosova; Mark Hull; Kanna Hayashi; Kora Debeck; M-J Milloy
Journal:  Liver Int       Date:  2019-02-24       Impact factor: 5.828

5.  Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study.

Authors:  Andreea A Artenie; Evan B Cunningham; Gregory J Dore; Brian Conway; Olav Dalgard; Jeff Powis; Philip Bruggmann; Margaret Hellard; Curtis Cooper; Philip Read; Jordan J Feld; Behzad Hajarizadeh; Janaki Amin; Karine Lacombe; Catherine Stedman; Alain H Litwin; Pip Marks; Gail V Matthews; Sophie Quiene; Amanda Erratt; Julie Bruneau; Jason Grebely
Journal:  Clin Infect Dis       Date:  2020-05-23       Impact factor: 9.079

6.  Direct-acting antiviral treatment uptake and sustained virological response outcomes are not affected by alcohol use: A CANUHC analysis.

Authors:  Matt Driedger; Marie-Louise Vachon; Alexander Wong; Brian Conway; Alnoor Ramji; Sergio Borgia; Ed Tam; Lisa Barrett; Dan Smyth; Jordan J Feld; Sam S Lee; Curtis Cooper
Journal:  Can Liver J       Date:  2021-08-09

7.  Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals.

Authors:  Marina Serper; Donna M Evon; Paul W Stewart; Anna S Lok; Jipcy Amador; Bryce B Reeve; Carol E Golin; Michael W Fried; K Rajender Reddy; Richard K Sterling; Souvik Sarkar; Adrian M Di Bisceglie; Joseph K Lim; David R Nelson; Nancy Reau
Journal:  J Gen Intern Med       Date:  2019-10-28       Impact factor: 5.128

8.  Strategies for the elimination of hepatitis C virus infection as a public health threat in the United States.

Authors:  Charitha Gowda; Vincent Lo Re
Journal:  Curr Hepatol Rep       Date:  2018-03-24

9.  Impact of Removing Medicaid Fee-for-Service Hepatitis C Virus (HCV) Treatment Restrictions on HCV Provider Experience with Medicaid Managed Care Organizations in New York City.

Authors:  Czarina N Behrends; Sarah Gutkind; Regan Deming; Kyle R Fluegge; Marie P Bresnahan; Bruce R Schackman
Journal:  J Urban Health       Date:  2021-08       Impact factor: 5.801

10.  The Effects of Hepatitis C Treatment Eligibility Criteria on All-cause Mortality Among People With Human Immunodeficiency Virus.

Authors:  Alexander Breskin; Daniel Westreich; Christopher B Hurt; Stephen R Cole; Michael G Hudgens; Eric C Seaberg; Chloe L Thio; Phyllis C Tien; Adaora A Adimora
Journal:  Clin Infect Dis       Date:  2019-10-15       Impact factor: 20.999
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.